Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
16.60
0.00 (0.00%)
Arcutis Biotherapeutics Inc is a biopharmaceutical company focused on developing innovative treatments for dermatological conditions
The company is dedicated to addressing unmet medical needs by leveraging its expertise in immunology and dermatology to create topical therapies that enhance the quality of life for patients suffering from skin disorders. Through its research and development efforts, Arcutis aims to deliver effective and safe solutions for common conditions such as psoriasis, eczema, and other inflammatory skin diseases, emphasizing patient-centric approach and scientific rigor in its product development pipeline.
FDA approved Arcutis Biotherapeutics' sNDA for Zoryve cream 0.15% for mild to moderate atopic dermatitis in patients aged six and older. Zoryve provides a steroid-free treatment option. Significant improvement in itch was observed within 24 hours of application.
